** Medadvisor MDR.AX slides 12.7% to A$0.096, lowest since March 21
** Medication solutions co expects FY25 loss before interest, taxes, depreciation and amortization to be in the A$2.6 mln ($1.6 mln)-A$5.5 mln range
** Co reported FY24 EBITDA at A$7 mln
** MDR expects FY25 revenue between A$93 mln and A$99 mln, lower than year-ago A$122 mln
** Stock on track for weakest session since March 21
** MDR sheds 51.1% YTD
($1 = A$1.6023)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。